Press Releases - 2023-01-25

Date	Title	Company
25-Jan-2023	PAION AG: Extraordinary General Meeting approves capital reductions and creates scope for further corporate financing	PAION AG
25-Jan-2023	Hip Replacement Market Size to Grow USD 8.6 Billion, Globally, by 2031 at 4.0% CAGR	Allied Market Research
25-Jan-2023	Artificial Blood Pump Market Size, Share, Growth Drivers and Opportunities 2023 to 2032 \| insightSLICE	insightSLICE
25-Jan-2023	Bivalent Human Papillomavirus Vaccine Market Size, Share, Growth Drivers and Opportunities 2023 to 2032 \| insightSLICE	insightSLICE
25-Jan-2023	Animal-Free (AF) Collagenase Market Size, Share, Growth Statistics 2023 to 2032 \| insightSLICE	insightSLICE
25-Jan-2023	Blackford and Brainomix Announce AI Partnership for Stroke Care	Blackford and Brainomix
25-Jan-2023	First Provider in Germany: CeGaT Offers Sequencing Services Based on PacBio's SMRT Technology	CeGaT
25-Jan-2023	Sosei Heptares Webinar Presentation for FY2022 Financial Results	Sosei Heptares
25-Jan-2023	STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference	STORM Therapeutics
25-Jan-2023	Neumentum Announces Initiation of Phase 3 Program Evaluating Its Lead Product Candidate, NTM-001, for the Management of Moderately Severe Acute Pain	Newswire
25-Jan-2023	Original-Research: Spexis AG (von First Berlin Equity Research GmbH)	Spexis AG
25-Jan-2023	Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor	Rewind Therapeutics
25-Jan-2023	Cell Therapy Market is estimated to be US$ 19.6 billion by 2030 with a CAGR of 13.1% during the forecast period	prophecy
25-Jan-2023	Transport Patient Monitor Market Size, Share, Growth Drivers and Opportunities 2023 to 2032 \| insightSLICE	insightSLICE
25-Jan-2023	Molecular Spectroscopy Market Analysis, Size, Share, Growth, Trends and Forecast 2023-2032 \| insightSLICE	insightSLICE
25-Jan-2023	Organic Acids Market is estimated to be US$ 18.6 billion by 2032 with a CAGR of 6.8% over the forecast period (2022-2032)	Prophecy Market Insights
25-Jan-2023	Lonza Delivers Strong 2022 Performance with 15.1% CER Sales Growth and 32.1% CORE EBITDA Margin	Lonza Group AG